Abstract Body

Background: DTG 50mg QD plus two N(t)RTIs has been compared to 3 preferred regimens in pivotal studies up to 96 weeks (SPRING2 and FLAMINGO) or 144 weeks (SINGLE) in treatment naïve patients. Consistency of the treatment difference was explored within key subgroups.

Methods: SPRING-2 randomized participants to DTG 50mg QD or RAL 400 mg BID, FLAMINGO randomized participants to DTG 50mg or DRV/r QD. In both studies, investigator selected NRTIs (TDF/FTC or ABC/3TC). SINGLE randomized participants to DTG 50 mg + ABC/3TC QD or TDF/FTC/EFV QD. Snapshot response rates were analyzed by NRTI backbone, baseline viral load and baseline CD4. Also, time to efficacy related failure, where withdrawals unrelated to efficacy are censored, were used for the week 96 pooled analyses and were summarised by NRTI backbone and baseline viral load.

Results: The three studies randomized and treated a total of 2139 subjects. Overall, there was no evidence of compromised efficacy in individuals on DTG with high viral load or low CD4s. Subgroup analysis of the Week 96 snapshot suggested that, in individuals with high viral load, there were similar response rates to DTG and EFV in SINGLE however, DTG had a higher response rate vs DRV/r in FLAMINGO. These apparent interactions were not consistent across studies or timepoints. In the SINGLE study, at Weeks 48 and 144, the response rate for patients with high VL at baseline receiving DTG was 7-8 percentage points higher than for those on EFV. Exploratory analyses examining time-to-efficacy related failure showed no difference in response rates between the background NRTIs pooled across the studies irrespective of baseline viral load. Additionally, there was no suggestion of a difference in efficacy related failures between DTG vs comparator agents at high or low viral load.

Conclusions:
In three large treatment-naïve studies, DTG was effective up to week 96 with both ABC/3TC and TDF/FTC, in subjects with high and low viral load and across CD4 strata. DTG is a once daily, unboosted INI that can be used effectively with either TDF/FTC or ABC/3TC backbone in treatment-naive, HIV-infected individuals.

viewer?TAG_ACTION=SECURE_FILE_DOWNLOAD&V